Digital PCR improves mutation analysis in pancreas fine needle aspiration biopsy specimens

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Sho, Shonan ^a,b   Court, Colin M ^a,b,c   Kim, Stephen ^a,c   Braxton, David R ^a   Hou, Shuang ^c   Muthusamy, V Raman ^a,c   Watson, Rabindra R ^a,c   Sedarat, Alireza ^a,c   Tseng, Hsian Rong ^c   Tomlinson, James S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Greater Los Angeles Veterans   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ARTICLE; CELL HETEROGENEITY; CLINICAL ARTICLE; CLINICAL DECISION MAKING; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED STUDY; DIGITAL POLYMERASE CHAIN REACTION; DILUTION; DNA DEGRADATION; DNA EXTRACTION; FINE NEEDLE ASPIRATION BIOPSY; GENE FREQUENCY; GENE MUTATION; GOLD STANDARD; HUMAN; INTERMETHOD COMPARISON; LASER MICRODISSECTION; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PANCREAS BIOPSY; PANCREAS CANCER; POINT OF CARE TESTING; POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION SYSTEM; PREOPERATIVE PERIOD; PROTEIN PURIFICATION; SANGER SEQUENCING; SENSITIVITY ANALYSIS; TUMOR CELL; DNA MUTATIONAL ANALYSIS; GENETICS; GENOTYPE; METABOLISM; MUTATION; PANCREAS; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROCEDURES; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

KRAS PROTEIN, HUMAN; PROTEIN P21;

BIOPSY, FINE-NEEDLE; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; GENOTYPE; HUMANS; MUTATION; PANCREAS; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS P21(RAS); SENSITIVITY AND SPECIFICITY;

EID: 85010991924     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0170897     Document Type: Article

References (30)

1. Hanahan D, Weinberg Robert A. Hallmarks of Cancer: The Next Generation. Cell. 2011; 144(5):646-74. doi: 10.1016/j.cell.2011.02.013 PMID: 21376230
2. Garrawa LA, Verweij J, Ballman KV. Precision oncology: An Overview. Journal of Clinical Oncology. 2013; 31(15):1803-5. Epub April 15, 2013. doi: 10.1200/JCO.2013.49.4799 PMID: 23589545
3. Kanagal-Shamanna R, Portier BP, Singh RR, Routbort MJ, Aldape KD, Handal BA, et al. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Modern Pathology. 2013; 27(2):314-27. doi: 10.1038/modpathol.2013.122 PMID: 23907151
4. LeBlanc JK C D, Al-Assi MT M K, Imperiale T, Tao LC, Vallery S, DeWitt J, Sherman S, Collins E. Optimal number of EUS-guided fine needle passes needed to obtain a correct diagnosis. Gastrointest Endosc. 2004; 59:475-81. PMID: 15044881
5. Graham JS, Jamieson NB, Rulach R, Grimmond SM, Chang DK, Biankin AV. Pancreatic cancer genomics: where can the science take us? Clinical Genetics. 2015; 88(3):213-9. doi: 10.1111/cge.12536 PMID: 25388820
6. Court CM, Ankeny JS, Hou S, Tseng H-R, Tomlinson JS. Improving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysis. Expert Review of Molecular Diagnostics. 2015; 15(11):1491-504. doi: 10.1586/14737159.2015.1091311 PMID: 26390158
7. Perincheri S, Hui P. KRAS mutation testing in clinical practice. Expert Review of Molecular Diagnostics. 2014; 15(3):375-84. doi: 10.1586/14737159.2015.986102 PMID: 25487540
8. Gonzalez de Castro D, Angulo B, Gomez B, Mair D, Martinez R, Suarez-Gauthier A, et al. A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens. Br J Cancer. 2012; 107(2):345-51. doi: 10.1038/bjc.2012.259 PMID: 22713664
9. de Biase D, Visani M, Baccarini P, Polifemo AM, Maimone A, Fornelli A, et al. Next generation sequencing improves the accuracy of KRAS mutation analysis in endoscopic ultrasound fine needle aspiration pancreatic lesions. PLoS One. 2014; 9(2):e87651. doi: 10.1371/journal.pone.0087651 PMID: 24504548
10. Huggett JF, Cowen S, Foy CA. Considerations for Digital PCR as an Accurate Molecular Diagnostic Tool. Clinical Chemistry. 2014; 61(1):79-88. doi: 10.1373/clinchem.2014.221366 PMID: 25338683
11. Bidshahri R, Attali D, Fakhfakh K, McNeil K, Karsan A, Won JR, et al. Quantitative Detection and Resolution of BRAF V600 Status in Colorectal Cancer Using Droplet Digital PCR and a Novel Wild-Type Negative Assay. The Journal of Molecular Diagnostics. 2016; 18(2):190-204. doi: 10.1016/j.jmoldx.2015.09.003 PMID: 26762843
12. Lamy P-J, Castan F, Lozano N, Montélion C, Audran P, Bibeau F, et al. Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies. The Journal of Molecular Diagnostics. 2015; 17(4):366-73. doi: 10.1016/j.jmoldx.2015.02.004 PMID: 25952101
13. Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends in Biochemical Sciences. 2014; 39(2):91-100. doi: 10.1016/j.tibs.2013.12.004 PMID: 24388967
14. Kinugasa H, Nouso K, Miyahara K, Morimoto Y, Dohi C, Tsutsumi K, et al. Detection of K-rasgene mutation by liquid biopsy in patients with pancreatic cancer. Cancer. 2015; 121(13):2271-80. doi: 10.1002/cncr.29364 PMID: 25823825
15. Ogura T, Yamao K, Hara K, Mizuno N, Hijioka S, Imaoka H, et al. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. Journal of Gastroenterology. 2012; 48(5):640-6. doi: 10.1007/s00535-012-0664-2 PMID: 22983505
16. Hamidi H, Lu M, Chau K, Anderson L, Fejzo M, Ginther C, et al. KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition. British Journal of Cancer. 2014; 111(9):1788-801. doi: 10.1038/bjc.2014.475 PMID: 25167228
17. Bournet B, Muscari F, Buscail C, Assenat E, Barthet M, Hammel P, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clinical and Translational Gastroenterology. 2016; 7(3):e157.
18. Bournet Barbara, Buscail Camille, Muscari Fabrice, Cordelier Pierre, Buscai L. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities. European Journal of Cancer. 2016; 54:75-83. doi: 10.1016/j.ejca.2015.11.012 PMID: 26735353
19. Lito P, Solomon M, Li L-S, Hansen R, Rosen N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2016; 351(6273):604-8. doi: 10.1126/science.aad6204 PMID: 26841430
20. Court CM, Ankeny JS, Sho S, Hou S, Li Q, Hsieh C, et al. Reality of Single Circulating Tumor Cell Sequencing for Molecular Diagnostics in Pancreatic Cancer. The Journal of Molecular Diagnostics. 2016;In press.
21. Azuara D, Ginesta MM, Gausachs M, Rodriguez-Moranta F, Fabregat J, Busquets J, et al. Nanofluidic digital PCR for KRAS mutation detection and quantification in gastrointestinal cancer. Clinical chemistry. 2012; 58(9):1332-41. doi: 10.1373/clinchem.2012.186577 PMID: 22745110
22. Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nature Medicine. 2008; 14(5):579-84. doi: 10.1038/nm1708 PMID: 18408729
23. Valero V 3rd, Saunders TJ, He J, Weiss MJ, Cameron JL, Dholakia A, et al. Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing: Implications for Surgical Management. Ann Surg. 2016; 263(1):153-61. doi: 10.1097/SLA.0000000000001156 PMID: 26020105
24. Takahashi K, Yamao K, Okubo K, Sawaki A, Mizuno N, Ashida R, et al. Differential diagnosis of pancreatic cancer and focal pancreatitis by using EUS-guided FNA. Gastrointestinal Endoscopy. 2005; 61 (1):76-9. PMID: 15672060
25. Ogura T, Yamao K, Sawaki A, Mizuno N, Hara K, Hijioka S, et al. Clinical impact of K-ras mutation analysis in EUS-guided FNA specimens from pancreatic masses. Gastrointestinal Endoscopy. 2012; 75 (4):769-74. doi: 10.1016/j.gie.2011.11.012 PMID: 22284089
26. Bournet B. Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer. World Journal of Gastroenterology. 2014; 20(31):10758. doi: 10.3748/wjg.v20.i31.10758 PMID: 25152579
27. Ankeny JS, Court CM, Hou S, Li Q, Song M, Wu D, et al. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. Br J Cancer. 2016; 114(12):1367-75. doi: 10.1038/bjc.2016.121 PMID: 27300108
28. Fuccio L, Hassan C, Laterza L, Correale L, Pagano N, Bocus P, et al. The role of K-ras gene mutation analysis in EUS-guided FNA cytology specimens for the differential diagnosis of pancreatic solid masses: a meta-analysis of prospective studies. Gastrointestinal Endoscopy. 2013; 78(4):596-608. doi: 10.1016/j.gie.2013.04.162 PMID: 23660563
29. Nikiforova MN, Khalid A, Fasanella KE, McGrath KM, Brand RE, Chennat JS, et al. Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts. Modern Pathology. 2013; 26(11):1478-87. doi: 10.1038/modpathol.2013.91 PMID: 23743931
30. Arvanitakis M, Van Laethem JL, Parma J, De Maertelaer V, Delhaye M, Devière J. Predictive Factors for Pancreatic Cancer in Patients with Chronic Pancreatitis in Association with K-rasGene Mutation. Endoscopy. 2004; 36(6):535-42. doi: 10.1055/s-2004-814401 PMID: 15202051